RxDoctor Payments Data

Bernardo Franssen Canovas, MD

Surgical Oncology · Charleston, SCNPI 1811251366

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (58.1%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 97.0% of it on its own, with 6 other manufacturers making up the rest.

$10,320in general payments, 2019–2025

Across 35 payments — averaging $294.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$10K
  • AbbVie$213
  • Merck$25
  • Stryker$25
  • Solventum Corporation$18
  • Olympus America Inc.$16
  • plus $14 from 1 others

What the payments were for

  • Travel & lodging$3,51634%
  • Food & beverage$7918%
  • Education$6,00058%
  • Gifts$140%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Intuitive Surgical24$10,009
AbbVie(2 entities)6$213
Merck1$25
Stryker1$25
Solventum Corporation1$18
Olympus America Inc.1$16
Novartis1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few surgical oncology providers in South Carolinato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$134,815
Medicare patients
226
Services billed
580

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase11$42,215
Oxycodone Hcl14$22

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$213$42,21511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few surgical oncology providers in South Carolinaon file to place this against a meaningful peer group, so we don't.

Other surgical oncology in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →